Inflection Phase Information

Inflection Phase, llc., is a regulatory science consultancy for the biotechnology and pharmaceutical industry. The company focuses on strategies to maximize value inflection points during the product lifecycle. With advances in basic science, dramatic downturns in global financing, and looming patent terminations, the biopharmaceutical industry is facing unprecedented challenges. Large and small companies are seeking business models that can adapt to global challenges. Inflection Phase operates one such innovative model. Utilizing a virtual structure that takes advantages of a global network of proven interdisciplinary experts, the Inflection Phase consultancy merges contemporary scientific knowledge with commercial considerations. “By bringing together diverse and experienced people, we provide modern strategies to tackle many urgent development challenges,” says Dr. Richard Williams, Executive in Residence at Inflection Phase. Williams added, “the industry has undergone, and continues to undergo, enormous changes. Our contemporary business model is ideally positioned to help clients navigate and thrive in this new global landscape.” Both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have announced regulatory science initiatives to accelerate product development – these initiatives highlight the importance of regulatory science in the development process. By combining in-house and externally-partnered expertise, Inflection Phase delivers comprehensive core competencies in regulatory science, from formulating translational proof-of-concept strategies through to expansion of existing therapies into emerging markets.